Five years of clinical experience with intermittent cyclical etidronate for postmenopausal osteoporosis.

Abstract

Five years of etidronate therapy for postmenopausal osteoporosis results in significant increases in vertebral bone mineral content, and the previously observed reduction in vertebral fracture rate in the etidronate group is maintained during at least 5 years of therapy.